Skye BioScience Joins Piper Sandler Virtual Obesity Day

SAN DIEGO, June 25, 2024 - Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative drugs that target the endocannabinoid system, has announced its participation in the Piper Sandler Virtual Obesity Day. This event, scheduled for June 26, 2024, will feature key opinion leader (KOL) presentations and interactive discussions with companies engaged in developing obesity treatments. Piper Sandler clients can register for the event through their representatives.

Skye Bioscience's team will partake in a Fireside Chat from 11:30 to 11:55 a.m. ET. The discussion will include insights from Punit Dhillon, CEO & Chair, Tu Diep, MSc, Chief Development Officer, and Chris Twitty, PhD, Chief Scientific Officer.

Skye Bioscience focuses on harnessing the therapeutic potential of the endocannabinoid system to address diseases characterized by metabolic, inflammatory, and fibrotic processes. Supported by specialized life science investors, Skye's strategy involves leveraging biologic targets with substantial human proof of mechanism. This approach aims to develop first-in-class therapeutics with significant clinical and commercial potential.

One of the company's key initiatives is the anticipated commencement of a Phase 2 clinical trial for Nimacimab in obesity, expected to begin in the third quarter of 2024. Nimacimab is a negative allosteric modulating antibody that peripherally inhibits CB1 receptors. The trial will compare the effects of Nimacimab as a monotherapy and in combination with a GLP-1R agonist.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!